REPORTING RESULTS OF DIAGNOSTIC NGS-BASED TESTING — USER-CENTERED REDESIGN OF THE CLINICAL REPORT

Oleg Agafonov¹, Sigrun Vik², Kaja O. Kjølås² and Sharmini Alagaratnam¹

1. DNV, 1363, Høvik, Norway
2. EGG Design, Møllergata 4, 0179, Oslo, Norway

1 ABSTRACT

The transition of next-generation sequencing (NGS) from the research environment to clinical diagnostics has proven difficult, with exome and whole genome sequencing at various stages of implementation in Nordic hospitals. The clinical genomics report details key findings from the interpretation of NGS data and represents the core hand-off between specialized clinical genomics laboratories and the broader healthcare community. However, these text-heavy reports can be difficult to read: critical information may be scattered around the report, and vital information such as limitations of the test may not always be present. Misunderstanding of results, limitations or key findings can lead to incorrect therapeutic decisions, directly impacting patient management.

We applied the principles of user-centred design to redesign clinical reports to respond to user needs, while also incorporating existing recommendations and guidelines. We performed several rounds of needs gathering, first with producers of clinical genetics reports, then with clinicians with various level of experience in genetic testing. Based on the insights from a workshop and interviews, we created prototypes of reports which were evaluated in comparison to a set of simulated reports representing those currently in clinical production. Our results showed that the majority of evaluators found the redesigned reports to be clearer and easier to process, demonstrating the value of this approach.

2 INTRODUCTION

Next-generation sequencing (NGS) has been widely used for research purposes for over 15 years since the first generation of massive parallel sequencers appeared on the market (1), followed by its application in routine diagnostics. Nevertheless, the transition from the research environment to clinical diagnostics has proven difficult. NGS diagnostics for rare diseases is a complex procedure comprising multiple steps – collection and DNA extraction from a biological sample such as blood, then DNA sequencing and bioinformatic analysis, resulting in a lengthy list of genetic variants. On average a human genome differs from the reference genome at 4.1 million to 5.0 million sites (2), therefore a series of filtering steps are required to narrow down the search to variants potentially associated with a disease phenotype, before final manual interpretation of the candidate variants. Once a conclusion is reached, the diagnostic laboratory describes the result of the test in the clinical genomics report, along with information on how this result was obtained. The goal of this report is both to transfer this sophisticated information from diagnostic laboratories to the clinician managing the patient, and provide guidance for subsequent clinical decision making (3).

The complexity of NGS-based diagnostic test result originates in the inherent uncertainties of the testing procedure - only variants located in genes or non-coding parts of the genome deemed relevant for a specific disease phenotype are usually subjected to analysis; and only certain types of genetic variants are currently analysed, namely single nucleotide variants (SNVs), small insertions and deletions and copy number variants (CNVs), while other types (e.g. complex structural variants) are often excluded from the analysis today. Overall, the diagnostic yield of NGS-based diagnostic tests varies from 7 to 42%, depending on the type of test and condition, the availability of family members for analysis and the type of genetic variant (4–7). When identified, the reported molecular variant is assigned probability as a cause of the disease phenotype, reflecting the level of certainty (8,9). In contrast to many other types of tests, the absence of findings of a molecular cause of the disease phenotype does not necessarily imply the absence of disease, resulting in limited negative predictive value. In addition to pathogenic findings, some laboratories report variants of uncertain significance (VUS), a class of variants that do not have sufficient evidence to be classified as benign or pathogenic (10), but may have significance for the management of disease with future scientific discoveries (11–13), and should therefore be followed up on. Taken together, all these factors underline the challenges of transferring often subtle but critical diagnostic information. As a result, the topic of clinical reporting was nominated as one of the key challenges in NGS-based diagnostics by members of clinical genetics laboratories at a biannual Nordic Alliance for Clinical Genomics workshop (14).

In our previous study, we reviewed existing guidelines for clinical reporting and identified recommendations available in the scientific literature spanning various parts of the reporting process and report content (15). Among these recommendations, four areas were identified as especially challenging to implement: VUS, secondary findings, reanalysis and data delivery to patients. We also conducted a peer-review benchmarking of Nordic reports from NGS-based diagnostic tests where we provided fictional clinical cases to diagnostic laboratories and asked them to produce reports for these, which then were evaluated by specialists in medical genetics and NGS-based diagnostic testing. Through this benchmarking exercise, we found that even though evaluators scored the reports as high in clarity, they experienced difficulties in identifying the presence of key information in the report, for example if secondary findings were systematically searched for. This exercise indicated that even though laboratories were aware of the challenges surrounding clinical reporting, there is room for improvement in practice; in particular difficulties in comprehension of key information were identified as being due not only to report design and formatting, which can be limited by local IT production systems, but also methods for delivering the report to the requisitioning clinician (15).

Clinical reports currently in use in the Nordics have evolved along with the development of testing technologies and pre-existing IT report production infrastructure, and do not necessarily respond to user needs. In this work, we applied the principles of user-centred design (UCD) to redesign clinical reports according to user needs, while also incorporating existing recommendations and legislation identified in our previous study (15). UCD is an approach that incorporates the user's perspective into the product development process to achieve an adequate and usable product (16). This approach has been internationally accepted and defined as an ISO standard - ISO 9241-210 (17). The standard states six principles which should be considered for product development:

- product development should be based on users and their tasks and environments
- end-users should be involved in product design and development
- product development should be based on input from end-users

- the product development process should be iterative
- the design should address the whole user experience
- the design team should be multidisciplinary.

In the redesign process, we identified a range of potential report users through a workshop with clinical genetics laboratories from five Nordic countries: Denmark, Finland, Iceland, Norway and Sweden. To identify and analyze user needs for clinical reports in medical genetics, we conducted semi-structured interviews with clinicians and report producers. Taking into consideration the needs identified, we created prototype clinical reports utilizing a multidisciplinary team of designers and specialists in medical genetics and NGS diagnostics. Finally, we tested the prototypes with end-users by benchmarking the prototypes against simulated existing reports, identifying opportunities for iterative improvement.

3 METHODS

3.1 UNDERSTANDING THE CONTEXT OF USE AND IDENTIFYING USER NEEDS

3.1.1 Exploratory kick-off workshop with report producers

This workshop took place during the Nordic Alliance for Clinical Genomics meeting in Copenhagen in November 2018. Eighteen clinicians and diagnostic laboratory members from 5 Nordic countries participated in the workshop, during which main groups of clinical report users, existing activities and challenges were identified.

3.1.2 Semi-structured interviews with clinicians and patients

Sampling

Convenience and snowball sampling were used leveraging the internal and external networks of the research team and the Nordic Alliance for Clinical Genomics to recruit clinicians and NGS diagnostic laboratories staff for interviews.

Data collection

Semi-structured interviews were focused on exploring interviewees' perspectives based on their experiences of receiving reports. Interviews lasted between 45 to 90 minutes and were conducted between February and April 2019. List of interview questions can be found in Appendix 1, Table 1.

Data analysis

The interview responses (n=9) were collated for content analysis. Significant words or phrases were extracted from interview notes. The words and phrases with similar meanings were categorized together and organized into common themes. Taking an iterative approach, a series of workshops were held among the researchers to discuss and condense the themes and their descriptions. Team consensus was used to resolve any disagreement.

Ethical considerations

Interviewees participated voluntarily and all interviewees gave their consent verbally. Interview responses were anonymized and treated as highly confidential. Only the research team had access to

the responses. In terms of GDPR compliance, a clear project policy was developed of not receiving or recording any personal information, and communicated to all project members.

3.2 PRODUCING PROTOTYPE REPORTS

Interviews were analysed individually by the project team consisting of both design and clinical genetics experts to extract challenges related to the process of information transfer in clinical NGS reporting. Storyboarding was used to capture the key moments of the user journey into stories to support visual ideas. The insights gathered through this were grouped according to themes, and ideation methods were used to visualize potential solutions responses to these needs. Wireframes, or quick, low-fidelity sketches, were first developed to address the main concepts of layout and usability. Design modules for combinatorial use were refined. Finally, prototype and prototype elements were identified and prioritized on the modular components, in collaboration with clinicians and researchers.

3.3 EVALUATING THE PROTOTYPE REPORTS

A survey for report producers and users was designed to validate the redesigned clinical reports prototypes and test the accuracy of data flow from producer to user, and user satisfaction. Each participant received two sets of reports: the first set simulated current reports and contained the main elements of a clinical NGS report, highlighted with colour and structured with tables. We used a simulation, rather than in-production reports for benchmarking to avoid familiarity bias. The second set contained the redesigned prototype reports (see Appendix 2). Both sets contained three fictional clinical cases: the first with a likely pathogenic finding, the second with a VUS and a secondary pathogenic finding in the *BRCA2* gene, and the third with no findings of clinical significance. Participants, clinicians with various level of familiarity with NGS-based testing (n=8) were asked to answer a series of questions for each report, where the survey contained Likert scale questions, 'Yes' or 'no' questions and open-ended questions (see Appendix 1, Appendix Table 2). Surveys allowed for additional qualitative feedback on topics discussed.

4 RESULTS

4.1 REDESIGN PROCESS OVERVIEW

To redesign clinical reports, we utilized UCD methodology by first conducting a workshop with report producers to identify the full spectrum of report users, main challenges in clinical reporting, and to conceptualize ideal solutions. We then conducted a series of semi-structured interviews (n=9) with report users: clinicians with various levels of familiarity with genetic testing, various frequency of communication with diagnostic laboratories and of various ages. After that, we developed discrete report modules, where each module addressed a specific aspect of a report (e.g. patient information, results, conclusion, etc.) which could be modified separately and combined in various layouts. These modules were used to produce prototypes that were tested on a small number of clinicians and report producers; and insights from testing used to modify the report's structure and content. Finally, the resulting prototypes were tested in comparison to existing reporting solutions on a broader scope of clinicians; see Figure 1.

Figure 1. Process map of the redesign.

4.2 UNDERSTANDING AND SPECIFYING THE CONTEXT OF THE USE

4.2.1 The users and their characteristics

In an earlier study, we found wide variation among clinical professionals in how NGS-based testing reports are read and processed (15). To sufficiently address user needs, we needed to identify their characteristics. In a workshop with clinical genetics laboratories from five Nordic countries, we were able to identify several categories of clinical report users. The first consists of requisitioning clinicians, which is a diverse group of health personnel, ranging from general practitioners who only occasionally requisition genetic testing (several cases per year, we refer to this group as clinicians with less experience in genetic testing) to clinical specialists who requisition genetic testing regularly (several cases per week, we refer to this group as clinicians with a high level of competence in genetics), e.g. psychiatrists and neurologists at regional centres. The second group consists of producers of the report, laboratory personnel at hospitals who perform NGS testing. The third group of users are patients and patients' legal guardians. Although there was variation in how often clinicians provided clinical reports to their patients, some patients specifically requested these reports. In some cases, patients or patients' legal guardians may provide clinical reports to patient organizations for support and guidance. Clinicians also reported anecdotal cases of patients uploading their clinical reports to social networks/forums to discuss diagnosis, making them available for the general public.

In the workshop, producers were asked to nominate specific clinicians with a range of genetic literacy, ages and frequency of requisitioning clinical NGS tests for in-depth semi-structured interviews. Report producers also proposed their perceived needs and potential challenges of reports' users, which we used to create a questionnaire for the semi-structured interviews to identify user needs.

4.2.2 Processing content of a report by different groups of users

To investigate how the reports are used by clinicians, we conducted a series of semi-structured interviews. Questions addressed the process of initiating testing, receiving a report, processing its content, communication with the diagnostic laboratory and patients, and potential ideal solutions.

Variation in the way reports are perceived

We found significant variation in the way reports are read and processed by different categories of clinicians. Clinicians with a high level of competence in genetics were interested in receiving a detailed report to enable as complete as possible understanding of the diagnostics laboratory's findings. This group preferred reports without recommendations for the treatment (which is the current practice), believing this to be within their domain of responsibility. Clinicians with less experience in genetic testing were primarily interested in a clear test result (for example in an easy-to-understand "traffic light" representation), with specific suggestions for follow-up and/or disease management.

Variants of uncertain significance

Uncertain test results were particularly challenging for clinicians with less experience in genetic testing. VUS are variants that do not have sufficient evidence to be classified as pathogenic or benign, and some laboratories report these variants to ensure that requisitioning clinicians receive a complete overview of all variants. Clinicians with less experience in genetic testing had difficulties in understanding the relevance of such variants to the disease phenotype. Clinicians regularly dealing with NGS-based testing stated that they had no problem understanding the uncertain result, but also stated that communicating uncertain results to patients was challenging.

Negative test result

Similarly to uncertain findings, understanding the implications of a negative result was also challenging for clinicians with less experience in genetic testing, since it required a detailed understanding of the performed test, including its limitations.

Delivery of reports to patients

Although anecdotal evidence showed that some clinicians believed patients and/or their next-of-kin would not understand details of an NGS-based diagnostic report, they acknowledged that receiving a report with a clear diagnosis could help patients or patients next-of-kin to navigate societal structures and organizations to secure support for themselves or their child.

4.2.3 The environment of the report

Clinical reports were found to be most frequently delivered either as a paper letter, which is then scanned and attached to the patient's electronic health record, or directly as a scanned document. In both cases, the final document can often only be accessed as an image file, which does not allow the use of active hyperlinks to relevant sources of information such as databases or additional details regarding the testing procedure, or copying text. Several clinicians expressed concern that they needed to retype Human Genome Variation Society (HGVS) nomenclature terms or other technical details to search for additional information regarding reported variants, in a time-consuming and potentially error-prone process. In some cases, the report is scanned by administrative personnel, and the requisitioning clinician may not be notified about the received report, introducing additional delays to the patient receiving a diagnosis.

4.3 SPECIFYING THE USER NEEDS AND PRODUCING DESIGN SOLUTIONS

We collected user needs by interviewing report producers and users, and during the workshop with report producers. As a result, we identified areas that should be addressed in the redesign process of the report, summarized in

Table 1. To create a report prototype we utilized a modular design approach, where each module addresses specific tasks and user needs, Figure 2.

Table 1. User needs and proposed design solutions

Category	Subcategory	Needs of less experienced users	Needs of expert users	Solution for less experienced users	Solution for expert users
1. Content of a report	1.1 Clarity of the test result 1.2 Different report templates for different user groups 1.3 Complexity level adjusted to each user group, including patients	Clinicians with less experience are primarily interested in yes or no answer to if there is a molecular cause of the observed phenotype. A large number of details can overwhelm and distract from the main result. This group of users was also interested in which implications the test result has for disease management, including suggestions for treatment.	Experienced users were interested in a complete overview of the main results, and on how these were derived from the data with references to sources used. This group of users is interested in a detailed description of the diagnostic test, procedures of deriving the result and test limitations. This group also is interested in auxiliary sources, such as databases and literature.	<ul style="list-style-type: none">• A hierarchical display of the results: key information is displayed on the first page (Modules 5-7), detailed information is presented further in the report (Module 13).• Hierarchy of findings differentiated with visual elements and colour (e.g. Module 5).	<ul style="list-style-type: none">• References to the databases and literature (Module 13).• A detailed description of the test methodology and limitations in the appendix of the report (Module 17).
	1.4 Reporting VUS	Clinicians with less experience have limited understanding of VUS, and implications for further testing. They also find it challenging to accurately communicate VUS to patients.	Experienced clinicians are interested in complete information on all potentially relevant variants, including VUS. Nevertheless, they also find communication of VUS to patients challenging.	A link to a detailed description of VUS, including information on what implications a VUS may have, and best practices on how to communicate VUS to patients (Module 10).	
	1.5 Secondary findings	Both categories of clinicians wanted clear statements on if the laboratory performs secondary findings analysis, and what kind of secondary findings are returned (e.g. ACMG SF v2.0 gene list (18)).		If the analysis of secondary findings is performed by the diagnostic laboratory, the report should contain results of this analysis and their interpretation when relevant (Module 11). If any secondary findings have implications for the patient or family members, the report should contain the recommended follow-up (Module 12b).	
	1.6 Recommended follow-up: Recommendations for further testing	Both categories of clinicians would like to have recommendations for further testing in cases when only VUS are reported, or no causative variants are found.	Some experienced clinicians stated that there is no need in recommended follow-up in the report, as this is the domain of the clinician.	Recommended follow-up section with recommendations for further testing, in cases when only VUS are reported, or no causative variants are found (Module 12).	
	1.7 Recommended follow-up: Information about reanalysis	It has been established that regular reanalysis can result in the identification of causative variants in previously inconclusive tests (6–8). Nevertheless, current reports do not have information regarding the possibility of reanalysis. Both categories of clinicians would like to have information on the possibility of data reanalysis, particularly in inconclusive cases.		A module with details on reanalysis, its regularity and process of initiation can be included (Module 12c).	

	1.8 Report delivery format	Reports are frequently delivered as scanned letters in an image file. This format does not support hyperlinks to relevant databases and references, which experienced clinicians are interested in, or background or supplementary information for less experienced clinicians.	The report should be made available as an interactive PDF with active hyperlinks.
	1.9 Treatment recommendations	Most clinicians strongly believe that treatment suggestions should not be part of the report since it is the domain of the clinician managing the patient.	Treatment should not be part of the report unless it is a part of the information in databases.
2. Communication	2.1 Communication and collaboration channels	Both categories of clinicians expressed the need for communication with the diagnostic laboratory regarding the correct choice of test, testing procedures and possibilities of further testing. Currently, communication mainly occurs by phone, nevertheless, often no direct contact phone number is provided on the report, or in cases when a number is provided, it is unclear who the number is for. Clinicians expressed a need for multidisciplinary collaboration on challenging cases both nationally and internationally.	Providing a phone number and link to resources, where one can find information on available tests, requisitioning procedure, the time required to perform the test, waiting time and other relevant information (Module 2).
	2.2 Status of the testing progress	One of the most frequent communication topics between the diagnostic laboratory and requisitioning clinicians is a status of the ordered test.	As above for 2.1-2.2.
3. Patient care	3.1 Separate patient version of the report, with extended information	There is large variation in the extent to which the clinical report is made available to patients. Clinician expressed concern that the technical content of the report may be confusing and induce anxiety for patients not well versed in the terminology. Nevertheless, clinicians acknowledged that patients could benefit from access to the report. For example, in cases when a definitive molecular cause is established, the report can help to navigate societal and welfare administration, including gaining access to support and benefits.	Provide information relevant to patients in the report: contact person in case of questions and her contacts, links to relevant patient's groups (Module 15).

Ordering physician

Smith University Hospital
Genetics Lab

Dr. Jan Johansen

Oslo University Hospital Rikshospitalet

P.O. Box 4850 Nydalen

N-0424 Oslo, Norway

Brighton, 28.05.2019

Questions about this report?

See our website: www.smithgenetics.com/reports

Call our genetic specialists: +44 373-227000

Patient

Name: HØVIK, Anna

Gender: Female

Date of birth: 28.05.2013

Clinical indication and reported phenotypes

Arthrogryposis multiplex congenita (AMC), muscle hypotonia, global developmental delay. Brain MRI shows suspected dysgenesis and delayed myelination, microcephaly <3SD. Parents are healthy.

Sample information

Sample ID: Case2_AH

Sample type: Blood

Received: 24.04.2018

Analysis performed

Exome sequencing of proband, mother and father (Agilent SureSelect Human All Exon 60 Mb), and trio analysis of coding exons along with flanking +/-20 intronic bases.

Result

1 2 3 4 5

Uncertain

Uncertain findings

No certain cause of the Phenotype was found

Conclusion

Genomic variants are classified on a five-point scale to indicate the likelihood that the variant is associated with disease. In this case, no certain molecular cause of AMC was identified. However, biallelic variants of uncertain significance were identified in RARS. The family should be referred for genetic counseling. See further details and recommendations below.

Main findings

Gene	Variant	Zygosity	Classification
RARS	(NM_028873)c.668G>A (p.Arg223His)	Heterozygous, from father	3 - Uncertain significance
RARS	(NM_0028873)c.1568T>A (p.Met523Lys)	Heterozygous, from mother	3 - Uncertain significance

Homocysteine according to HGVS (v2.3.1) (www.hgvs.com/mutnomen)

Interpretation

RARS encodes a cytoplasmic tRNA synthetase for arginine, essential for translation from RNA to proteins. Pathogenic variants in RARS cause autosomal recessive hypomyelinating leukodystrophy type 9.

The patient is compound heterozygote for the variants c.668G>A (p.Arg223His) and c.1568T>A (p.Met523Lys) in RARS. The variants are inherited from her father and mother, respectively. The variants p.Arg223His and p.Met523Lys are present in 8 and 0 individuals in a database of presumed healthy individuals, respectively, but have previously not been reported in patients with AMC. Our knowledge about these variants is not sufficient to conclude whether they are the cause of AMC or not. The family should be referred for genetic counseling for more information.

Page 1 of 3

Anna Hgvik - Sample ID Case2_AH

Smith University Hospital, Genetics Lab

About Variants of Unknown Significance (VUS)

Read more about how VUS are classified, interpreted and reported: www.smithgenetics.com/vus

Secondary findings

Gene	Variant	Zygosity	Classification
BRCA2	(NM_000059.3)c.8648delC (p.Pro2883Hisfs)	Heterozygous, from mother	5 - Pathogenic

Interpretation

In agreement with the patient consent, we report that a heterozygous pathogenic variant in BRCA2 (c.8648delC, p.Pro2883Hisfs) was identified in the patient. This variant confers an increased risk of malignant breast- and ovarian tumors. The variant is inherited from the patient's mother. We highly recommend that Anna Hgvik's mother is offered genetic counseling.

Recommended follow-up

1. Refer family for genetic counseling

to inform about the limitations of the performed test, the significance of the results and options for further testing.

2. Offer patient's mother genetic counseling

regarding the unsolicited pathogenic findings in BRCA2.

3. Re-analysis in 1 year

Re-analysis may provide more specific findings in the future and is recommended for this patient in 1 year.

References

1. OMIM #160720

2. Database: [gnomAD, Broad Institute](http://gnomAD.broadinstitute)

Further information

Sender for sjeldne diagnoser: sjeldnediagnoser.no

Search ClinicalTrials.gov and ClinicalTrialsRegisterfor for clinical studies for AMC and related conditions.

Information to patients

Please contact the physician who ordered this test for help interpreting the results: Dr. Jan Johansen

See our website www.smithgenetics.com/patient for general information and a list of genetic specialists and counselors in your area.

Page 2 of 3

Anna Hgvik - Sample ID Case2_AH

Smith University Hospital, Genetics Lab

Disclaimer

Exome sequencing covers approximately 95 % of the genomic variation located on protein coding regions. The analysis is mainly targeted to the coding regions and intronic splice site regions of genes. Exome sequencing does not cover all the intronic regions or all non-coding regions, such as UTRs (untranslated regions) of the genes. Some genomic regions, such as regions with repetitive elements or genes with nearly identical copies/pseudogenes, can not reliably be analyzed by exome sequencing.

Methods used

Blood samples from the family trio were collected on dd.mm.yyyy and received for DNA extraction on dd.mm.yyyy. RNA capture baits against approximately 60 Mb of the Human Exome (targeting >99% of regions in CCDS, RefSeq and Gencode databases) was used to enrich regions of interest from fragmented genomic DNA with Agilent's SureSelect Human All Exon V6 kit. The generated library was sequenced on an Illumina NextSeq 500 System to obtain an average coverage depth of > 80x. An end-to-end in-house bioinformatics pipeline was applied including conversion of base calls to fastq files (bcl2fastq Conversion Software v2.20), alignment of reads (bwa v. 0.7.17) to GRCh37/hg19 genome assembly, preprocessing of alignment files (GATK v3.8.1), variant calling (GATK Haplotype caller v3.8.1), variant filtering and annotation (Illumina Variant Studio 2.2). Identification of structural variants was not part of the pipeline. Evaluation was focused on coding exons along with flanking +/-20 intronic bases in a respective in silico gene panel, included genes are listed down. All identified variants were evaluated with respect to their pathogenicity and causality, and were categorized into 5 classes according to ACMG guidelines. Only rare variants with AF < 0.01 currently associated with patient phenotype were verified and reported. Verification was done by Sanger sequencing. Variants in genes listed in ACMG SF v2.0, www.ncbi.nlm.nih.gov/clinvar/docs/acmg/ classified as pathogenic or likely pathogenic were also reported if patients consented to receiving secondary findings.

Included genes

75 genes are included in the Arthrogryposis gene panel. For detailed information on the gene panel visit www.smithgenetics.com/panels/arthrogryposis/. In total the gene panel covers a maximum of 100% of the combined coding regions - 2bp intronic sequence of the following genes:

A	B	F	G	L	R	V
ABCA1	BLOC1C3	F10	GATA1	LYST	RASGRP2	VPAS39
ABCA4	BLOC1C8	F11	GF11B	M	RARS	VP533B
ABCG5	C	F13A1	GP1BA	MPG1B	S	W
ABCG8	COL1A1	F13B	GP1BB	MPL	SERPINE1	
ACTN1	COL3A1	F2	GP6	MYH9	SERPINF2	
ACVR1	COL5A1	F2R	GP9	N	SLFN14	
ADAMTS13	COL5A2	F2RL3	H	NBEA	SMAD4	
ADRA2A	CDC43	F5	HOXA11	NBEAL2	SRC	
ANKRD18A	D	F7	HR23B	O	STM1	
ANKRD26	DIAPH1	F8	HPS3	ORAI1	STX11	
ANOS6	DTNBP1	F9	HPS4	ORAI1	STXBP2	
AP3B1	ETNV6	FERMT3	HR23B	P	T	
ARPC1B	ENG	FGA	HR23B	P2RY1	TBA2R	
ANKRD26	ETNV6	FGG	I	P2RY12	TBA451	
AP3B1	ETNV6	FLI1	ITGA2	P4HB	THBD	
AP3D1	ETNV6	FLNA	ITGA2B	PLA2GAA	THPO	
ARPC1B	ETNV6	FYB	ITGB3	PLAU	TPM4	
				PRKACG	TUBB1	
				PTGS1		

Page 3 of 3

Figure 2. Example of a redesigned clinical report. 1 – header with information on requisitioning clinician and diagnostic laboratory; 2 – contact information with phone number and a web-link to laboratory information site; 3 – patient details, including description of phenotype; 4 – information on sample; 5 – main result, including colour-coded category; 6 – summary of test conclusion; 7 – main findings (a) and their interpretation (b); 8 – footer with number of page number and total number of pages; 9 – header with patient name and sample ID; 10 – supplementary information on VUS (present only in reports that contain VUS); 11 – secondary findings (a) details and (b) interpretation (present only in reports that contain secondary findings); 12 – recommended follow-up with recommendations on genetic counselling (a,b), recommended reanalysis (c); 13 – relevant references; 14 – further information with links to relevant clinical trials and other relevant information; 15 – information for patients including details on who to contact in case of questions, and relevant links with information on genetic testing, patients groups, etc.; 16 – disclaimer stating test limitations; 17 – methodology of genetic testing; 18 – list of tested genes (or in cases when the list is too long, a link to this list).

4.4 EVALUATING THE DESIGN

During the evaluation, we aimed to test if the redesigned reports performed better in comparison to the simulation of an existing report. Simulated reports were created based on the combination of the production reports of participating institutions – Oslo University Hospital in Norway, Rigshospitalet in Denmark, and HUSLAB in Finland. During the report simulation, we attempted to create a report which resembles reports from our partners instead of using existing actual partner reports to avoid familiarity bias during the evaluation.

During the evaluation, participants were asked a series of questions addressing various parts of the reports; see Figure 3. In addition, we recorded and analysed comments made by evaluators.

Visual appearance

Participants found redesigned reports more visually attractive and easier to navigate, stating the structure to be clearer and more intuitive. In particular, evaluators found that a clear representation of the main result, including a clear indication of the class of reported variants (Module 5), made it easier to read the report.

Recommended follow-up

Evaluators noted that recommended follow-up section (Module 12) is clear and useful, however, some expressed concern that opinion of a clinician responsible for the patient may differ from the opinion of the laboratory stated in the recommended follow-up, which may cause conflict in patient management.

Reanalysis policy

Evaluators expressed a preference for information regarding reanalysis policy (Module 12c) to be present in all reports, while in redesigned reports it was available only in reports without findings and reports with VUS.

References

Evaluators noted that references to relevant scientific publications and databases (Module 13) were helpful when additional information is needed for assessing the patient.

Supporting information

Evaluators stressed the importance of the appendix with supporting information, including methodology, limitations (Modules 16-17) and list of genes (Module 18), stating that this should always be present in the report.

Secondary findings

Some evaluators stated that it was not clear to them if secondary findings were present in the redesigned reports, and this information should be more clearly presented. A potential solution could be a module on a first page of the report, clearly stating presence or absence of secondary findings.

Figure 3. Validation of redesigned reports with a survey. A. Validation test design. B Summary of the survey result for Likert scale questions.

DISCUSSION

In this work, we utilised a user-centred design methodology to redesign an NGS-based clinical test report. Through the process of insight gathering from report users, we better understood the cause of variation on how a clinical report is processed by various groups of users. Through this, we were also better placed to address the main challenge of redesigning this report: that the same report is delivered to and must respond to different groups of users with different levels of genetic literacy and needs. The main strategy applied to overcome this challenge was to apply a clear hierarchy in the modular visualization of the results in the report, highlighting the key results of the test and recommended follow-up for the clinicians who are most interested in these. At the same time, more detailed information such as references to relevant literature sources and databases were made available for clinicians who were keen to access and process this information, as well as a detailed description of the methodology, test limitations, and list of tested genes being specified in the report's appendix.

A clinical report with a confirmed diagnosis can act as important documentation for patients to access support and welfare benefits, and both according to our survey and as reported earlier, patients do in fact often receive clinical reports (19). Despite this, and the impact of a confirmed diagnosis or the lack thereof being greatest for the patient, current versions of the reports of the laboratories that participated in our study lack supporting information for understanding the report for patients and/or their next of kin. Ideally, patients should have access to genetic counselling to answer their questions related to their diagnosis. However, patients may have additional questions at various stages, particularly in the case of uncertain or no findings. Some laboratories provide a separate report for patients (19), nevertheless this approach burdens laboratories with additional work, and is not scalable with the increasing number of genetic tests performed unless a higher degree of automation is used in report production. In the redesigned report prototype we attempt to address patients' needs by including a contact number, links to relevant sources of information about genetic testing, their disease and relevant patient support groups. This gives the patient recourse to contact information, answers to their initial questions, and navigates to trustworthy sources of information.

The clinical report is an important and tangible deliverable during the process of diagnostic NGS testing, yet continuous communication between the diagnostic laboratory and requisitioning clinicians is critical for the final outcome. Clinicians who requisitioned genetic testing more frequently reported a lower threshold for contacting the diagnostic laboratory with questions regarding an appropriate choice of test than clinicians who requisitioned genetic testing more rarely. At the same time, diagnostic laboratories reported that clinicians who requisitioned genetic testing more rarely are less likely to provide all the information necessary for the most appropriate test to be chosen. Similarly, upon receiving the clinical report, expert users are more comfortable and more frequently contact the diagnostic laboratory for additional information when needed than less experienced requisitioners. We positioned contact information for the diagnostic laboratory strategically in the redesigned reports and used language intended to lower the threshold for any reader of the report to take contact in case of any questions, and generally to encourage communication.

In this work, we attempted to create prototype reports responding to user needs that can be implemented within a reasonable timeframe. Despite this, the barriers represented by rigid IT infrastructure and production systems for implementing design solutions should not be underestimated, where anecdotal

evidence shows instances where only plain text can be entered to report the result of a diagnostic test. However, with the evolution of IT infrastructure over time, there is room for further improvement of the delivery of clinical reports, and indeed overall communication and interaction between requisitioning clinicians, diagnostic laboratories and patients, from assistance with test requisition, status of the testing process and dialogue after the test result is ready.

Conclusion

The clinical NGS report serves to transmit the results of this diagnostic test to requisitioning clinicians who have variable knowledge and level of experience with such tests, leading to wide variation in how the report is read and perceived. Complex information needs to be presented clearly, yet without oversimplification to the point of potentially misleading clinical decisions. Many current reporting solutions have not been designed per se, but rather represent inherited properties of reports for other types of tests, and genetic testing laboratories often lack resources and in-house UX competence to design a report. The reports delivered by commercial providers of genetic tests or analysis tend to be an exception, nevertheless these reports also vary in comprehensiveness and usability. Here we have attempted to meet user needs by creating clinical NGS report prototypes with differentiated levels of information comprising of individual modules, which can be entirely or flexibly integrated with existing reporting systems used in clinics. The created report prototype is distributed with a [Creative Commons knowledge license](#), and can be freely used for non-commercial purposes.

Acknowledgements

The research was conducted with the support of Design and Architecture Norway, grant number 295393. The authors thank clinicians and members of clinical genetic laboratories for participating in interviews, workshops and surveys. The authors thank Morten C. Eike, Bobbie Nicole Ray-Sannerud, Tita Alissa Bach and Courtney David Nadeau for reviewing the manuscript draft, Kaja Kvello and Tita Alissa Bach for assisting with organization, execution and processing of interviews and workshops.

APPENDIXES

Appendix 1. Interviews questions.

Appendix 2. Redesigned reports for the three fictitious cases used for testing.

REFERENCES

1. Tucker T, Marra M, Friedman JM. Massively Parallel Sequencing: The Next Big Thing in Genetic Medicine. *American Journal of Human Genetics*. 2009.
2. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, et al. A global reference for human genetic variation. *Nature*. 2015.
3. McLaughlin HM, Ceyhan-Birsoy O, Christensen KD, Kohane IS, Krier J, Lane WJ, et al. A systematic approach to the reporting of medically relevant findings from whole genome sequencing. *BMC Med Genet*. 2014;
4. Wright CF, FitzPatrick DR, Firth H V. Paediatric genomics: Diagnosing rare disease in children. *Nature Reviews Genetics*. 2018.
5. Lee B, Tran B, Hsu AL, Taylor GR, Fox SB, Fellowes A, et al. Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. *Intern Med J*. 2018;
6. Vissers LELM, Van Nimwegen KJM, Schieving JH, Kamsteeg EJ, Kleefstra T, Yntema HG, et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. *Genet Med*. 2017;
7. Lionel AC, Costain G, Monfared N, Walker S, Reuter MS, Hosseini SM, et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. *Genet Med*. 2018;
8. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med*. 2015 May 5;17(5):405–24.
9. Riggs ER, Andersen EF, Cherry AM, Kantarci S, Kearney H, Patel A, et al. Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). *Genet Med*. 2019;
10. Vears DF, Sénécal K, Borry P. Reporting practices for variants of uncertain significance from next generation sequencing technologies. *Eur J Med Genet*. 2017 Oct;60(10):553–8.
11. Al-Nabhani M, Al-Rashdi S, Al-Murshedi F, Al-Kindi A, Al-Thihli K, Al-Saegh A, et al. Reanalysis of exome sequencing data of intellectual disability samples: Yields and benefits. *Clinical Genetics*. 2018;
12. Schmitz-Abe K, Li Q, Rosen SM, Nori N, Madden JA, Genetti CA, et al. Unique bioinformatic approach and comprehensive reanalysis improve diagnostic yield of clinical exomes. *Eur J Hum Genet*. 2019;
13. Wright CF, McRae JF, Clayton S, Gallone G, Aitken S, FitzGerald TW, et al. Making new genetic diagnoses with old data: iterative reanalysis and reporting from genome-wide data in 1,133 families with developmental disorders. *Genet Med*. 2018;
14. Nordic Alliance for Clinical Genomics. Workshop Summary Report. 2018.

15. Nadeau C, Alagaratnam S, Agafonov O, Pedersen GM, Ray-Sannerud BN, McAdam S, et al. Clinical reporting of NGS-data – a systematic Nordic collaborative, peer-reviewed benchmarking. 2018.
16. Teixeira L, Ferreira C, Santos BS. User-centered requirements engineering in health information systems: A study in the hemophilia field. *Comput Methods Programs Biomed.* 2012;
17. International Organization for Standardization. ISO 9241-210: Ergonomics of human–system interaction - Human-centred design for interactive systems. International Organization for Standardization. 2019.
18. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. *Genet Med.* 2017 Feb 17;19(2):249–55.
19. Tarczy-Hornoch P, Amendola L, Aronson SJ, Garraway L, Gray S, Grundmeier RW, et al. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. *Genet Med.* 2013;